Ketek® (telithromycin) – Drug Discontinuation

- On March 11, 2016, the FDA announced that Sanofi Aventis discontinued the manufacturing of Ketek (telithromycin) 300 mg and 400 mg tablets.
  - The decision to discontinue Ketek was due to business reasons.
  - The last batch of Ketek expires in June 2016. The inventory of Ketek will be available until supply is depleted.

- Ketek is a ketolide antibacterial drug indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae (including multi-drug resistant S. pneumoniae), Haemophilus influenzae, Moraxella catarrhalis, Chlamydia pneumoniae, or Mycoplasma pneumoniae, for patients 18 years or older.

- For additional questions about the discontinuation of Ketek, contact Sanofi Aventis at 800-981-2491.